ASX / Media Release **3 August 2011**

RHT: FDA Clearance to Market Cardiac Iron Test in US

Resonance Health Ltd is pleased to announce that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its cardiac iron test, called MRI-Q, in the United States. The test measures an MRI parameter known as cardiac T2* which is highly sensitive to cardiac iron loading.

This follows the Health Canada approval received by the Company in July 2011 and TGA and CE Mark approvals obtained in 2010.

This announcement represents an important step forward for the Company. Resonance Health has received considerable demand for the cardiac T2* iron test from its existing US customers and anticipates strong uptake in this market.

Cardiac iron overload is the major cause of death in β-thalassaemia major patients. A service to provide an accurate non-invasive test for both liver and cardiac iron measurements will be made available to clinicians, offering significant improvement to patient management and outcomes.

The Company will also explore opportunities to provide this new test to clinical trials concerned with the assessment of iron overload therapies.

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Colin McDonald
Company Secretary
T: +61 8 9286 5300
E: colinm@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.